Skip to main content

US Regulators Clear Agilent to Buy Stratagene

NEW YORK (GenomeWeb News) — The US Federal Trade Commission has cleared Agilent Technologies’ proposed acquisition of Stratagene, according to a notice on the FTC’s website.
 
Agilent in April offered to buy Stratagene for $246 million, or $10.94 per share.
 
At the time, Stratagene CEO Joseph Sorge said he plans to form a new company that will pay $6.6 million for some of Stratagene’s molecular diagnostics assets.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.